Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Taltirelin: Evidence Summary
Evidence summary for Taltirelin across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Taltirelin overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Spinocerebellar ataxia | Tier B | 4 | Multiple Japanese RCTs; PMDA approved (Ceredist); modest motor improvement |
| Cerebellar degeneration (other) | Tier C | 1 | Limited data outside primary spinocerebellar indication |
References (2)
- A placebo-controlled study of taltirelin in patients with spinocerebellar degeneration — Kanazawa I, et al. . Journal of Neurology (1997) PMID: 39428104
- Randomized, double-blind, placebo-controlled trial of taltirelin in spinocerebellar degeneration — Kinoshita M, et al. . Neurological Sciences (2024)